Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant

In vitro assays demonstrated BA.2 would not be susceptible to sotrovimab, so distribution of the therapy will be paused in 8 states, Puerto Rico …